Infant Formula Tocopherol Blend for CNS Development
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current infant formulas often contain high levels of non-RRR alpha-tocopherol isomers, which compete with RRR alpha-tocopherol for absorption, potentially hindering brain and central nervous system development by reducing the efficacy of RRR alpha-tocopherol in stimulating postnatal CNS development and cognitive functions.
Innovation Solution
A nutritional composition with a balanced tocopherol blend, featuring a weight ratio of RRR alpha-tocopherol to RRR gamma-tocopherol ranging from 2:1 to 20:1, and limited non-RRR alpha-tocopherol isomers, is administered to enhance brain development and CNS maturation, optimizing the absorption and efficacy of RRR alpha-tocopherol.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If infant formulas contain high levels of non-RRR alpha-tocopherol isomers, then the formulation is simpler and less costly, but the absorption and efficacy of RRR alpha-tocopherol is reduced, hindering brain and CNS development
Solution Approach 1:
The patent extracts and removes the harmful non-RRR alpha-tocopherol isomers from the tocopherol mixture, leaving only the beneficial RRR alpha-tocopherol and RRR gamma-tocopherol in a controlled ratio. This extraction of the harmful component eliminates the competition for absorption while maintaining the nutritional benefits.
Solution Approach 2:
The patent changes the compositional parameters of the tocopherol blend by specifying a precise weight ratio range of RRR alpha-tocopherol to RRR gamma-tocopherol (2:1 to 20:1) and limiting non-RRR alpha-tocopherol isomers to less than 8 mg/L. This parameter optimization ensures maximum absorption and efficacy for brain development.
2Reliability
If infant formulas use a balanced tocopherol blend with optimized ratio, then the absorption and efficacy of RRR alpha-tocopherol is maximized, but the formulation complexity and manufacturing precision requirements increase
Solution Approach 1:
The patent defines specific parameter ranges for the tocopherol blend (weight ratio of RRR alpha-tocopherol to RRR gamma-tocopherol from 2:1 to 20:1, and non-RRR alpha-tocopherol isomers less than 8 mg/L) that optimize absorption and efficacy. These parameter specifications provide clear manufacturing targets while ensuring functional reliability.
Solution Approach 2:
The patent applies local quality by specifying different concentration levels and ratio requirements for different tocopherol components within the blend. RRR alpha-tocopherol and RRR gamma-tocopherol are maintained in a specific ratio range, while non-RRR isomers are strictly limited, creating a locally optimized composition for maximum brain development benefits.
Data Source
AI summary
This invention relates to a method of improving CNS maturation in an infant by administering a mixture of natural tocopherols, wherein the composition contains an optimum tocopherol profile similar to that found in human breast milk, and can encompass a tocopherol profile from early stage to transitional to mature human breast milk. For ease of administration and maximized efficacy, the optimized mixture of natural tocopherols are typically delivered in an oral dosage form with a limited level of non-RRR alpha-tocopherols to maximize efficacy of the RRR alpha-tocopherol on stimulating post-natal CNS development.